NLS Acquisition

Mölnlycke Health Care has signed an agreement to acquire P.G.F. Industry Solutions, the Austrian manufacturer of Granudacyn, a range of solutions for wound cleansing and moisturizing. Mölnlycke and P.G.F. have worked together for five years on the manufacturing and distribution of Granudacyn, a range of solution and gel products intended for use in the cleansing, […]

The US-based private equity firm has committed to acquire Recipharm’s sites in Solna, Strängnäs, Höganäs, Karlskoga and Uppsala OTC Development in Sweden, Pessac in France, and Parets in Spain. The colleagues at those sites form a new organisation under the leadership of Peter Kruger, Group Managing Director, states Recipharm. “The consolidation of our sites network […]

The two companies have entered into a definitive agreement for Genmab to acquire ProfoundBio in an all-cash transaction. Genmab will acquire ProfoundBio for USD 1.8 billion in cash, payable at closing. Genmab will acquire ProfoundBio for USD 1.8 billion in cash, payable at closing. “The proposed acquisition of ProfoundBio firmly aligns with our long-term strategy […]

Novo Nordisk has agreed to acquire Cardior for up to EUR 1.025 billion, including an upfront payment and additional payments if certain development and commercial milestones are achieved. Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. The […]

AstraZeneca has entered into a definitive agreement to acquire Canadian Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). Under the terms of the definitive agreement, AstraZeneca, through a subsidiary, will acquire all of Fusion’s outstanding shares pursuant to a plan of arrangement for a price of USD 21.00 per share in cash at […]

AstraZeneca has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. Under the terms of the agreement, AstraZeneca will acquire all of Amolyt Pharma’s outstanding shares for a total consideration of up to USD 1.05 billion, on a cash and debt free […]